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Cerebral beta-amyloidosis, one of the pathological hallmarks of Alzheimer’s disease (AD), elicits a well-
characterised, microglia-mediated local innate immune response. In contrast, it is not clear whether cells
of the adaptive immune system, in particular T-cells, react to cerebral amyloidosis in AD. Even though
parenchymal T-cells have been described in post-mortem brains of AD patients, it is not known whether
infiltrating T-cells are specifically recruited to the extracellular deposits of beta-amyloid, and whether
they are locally activated into proliferating, effector cells upon interaction with antigen-presenting cells
(APCs). To address these issues we have analysed by confocal microscopy and flow-cytometry the local-
isation and activation status of both T-cells and APCs in transgenic (tg) mice models of AD-like cerebral
amyloidosis. Increased numbers of infiltrating T-cells were found in amyloid-burdened brain regions of tg
mice, with concomitant up-regulation of endothelial adhesion molecules ICAM-1 and VCAM-1, compared
to non-tg littermates. The infiltrating T-cells in tg brains did not co-localise with amyloid plaques, pro-
duced less interferon-gamma than those in controls and did not proliferate locally. Bona-fide dendritic
cells were virtually absent from the brain parenchyma of both non-tg and tg mice, and APCs from tg
brains showed an immature phenotype, with accumulation of MHC-II in intracellular compartments.
These results indicate that cerebral amyloidosis promotes T-cell infiltration but interferes with local anti-
gen presentation and T-cell activation. The inability of the brain immune surveillance to orchestrate a
protective immune response to amyloid-beta peptide might contribute to the accumulation of amyloid
in the progression of the disease.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction cells and mature APCs found in the perivascular and meningealT-cells constantly patrol body tissues as part of the physiologi-
cal process of immune surveillance (von Andrian and Mackay,
2000). Upon recognition of their cognate antigen exposed on
mature antigen-presenting cells (APCs), T-cells undergo activation,
proliferate and exert effector functions, such as cytotoxicity in the
case of CD8+ T-cells and activation of macrophages and antibody-
producing B cells in the case of CD4+ T-helper cells. In the CNS,
physiological immune surveillance is mediated by patrolling T-spaces, and at the blood–cerebrospinal fluid (CSF) barrier of the
choroid plexus (CP) (Ransohoff et al., 2003; Ousman and Kubes,
2012).
In contrast to CSF-associated patrolling T-cells, T-cells retained
in the brain parenchyma often reflect an on-going pathology. In
autoimmune conditions such as multiple sclerosis, autoreactive
T-cells play a causative role in fostering macrophage-mediated
demyelination (Ciccarelli et al., 2014). In Alzheimer’s disease
(AD)-related neurodegeneration, characterised by the accumula-
tion of intracellular aggregates of abnormally phosphorylated tau
and extracellular deposition of aggregated amyloid-beta peptide
(Ab) (Selkoe, 2011), the role of the immune system is less well
understood (Town, 2010).
While several studies have demonstrated the presence of CD4+
and CD8+ T-cells in post-mortem brains of AD patients (Rogers et al.,
1988; Togo et al., 2002; Itagaki et al., 1988), their significance is a
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recruited to amyloid deposits in AD brains, and very little is known
on their activation status. Activated IFN-c producing-T-cells could
promote macrophage and microglia receptor-mediated phagocyto-
sis (Schroder et al., 2004), thus supporting beneficial clearance of
extracellular amyloid. On the other hand, overt T-cell activation
could result in direct cytotoxicity and macrophage-mediated tissue
damage, thereby contributing to neuronal demise (Aloisi et al.,
2000b). Hence, the activation state of the infiltrating T-cells might
be disease-relevant.
To elucidate this issue we have analysed T-cell numbers, local-
isation and phenotype in transgenic (tg) mouse models of AD-like
cerebral amyloidosis. We show that cerebral amyloidosis is associ-
ated with brain infiltration of T-cells, which do not co-localise with
amyloid deposits, do not proliferate locally and display low expres-
sion of the effector cytokine IFN-c.2. Materials and methods
2.1. Transgenic mice
ArcAb (Knobloch et al., 2007); APP-PS1-dE9 (Jankowsky et al.,
2004); Tg2576 (Hsiao et al., 1996); E22DAb (Kulic et al., 2012);
recombination activating gene 2 (RAG2) knockout mice (Shinkai
et al., 1992) were used. ArcAb and APP-PS1-dE9 were on a congenic
C57BL/6 background; Tg2576 were on a hybrid C57BL/6 and SJL
background; E22DAb were on hybrid C57BL6 and DBA/2 back-
ground. In each experiment we balanced the genders across geno-
types; no gender-specific effect was noted. The mice were kept in
OHB conditions, at 22 C ± 1 C and a 12 h light–dark cycle begin-
ning at 7:00 AM. Water and food were available ad libitum. Exper-
iments were conducted in accordance with the Swiss law for care
and use of animals (‘‘455.163 Tierversuchsverordnung” 2010) and
were approved by the veterinarian authorities of the Canton of Zur-
ich (license number 145/2014). This report adheres to the ARRIVE
guidelines for animal research.
2.2. Microbiological examination
Brains from two non-tg and two tg mice (2 year-old) underwent
the following microbiological examination: PCR for Lymphocytic
choriomeningitis, Theiler’s encephalomyelitis and mouse hepatitis
viruses; bacteriology culture (performed by MicroBioS GmbH,
Reinach, Switzerland).
2.3. Flow-cytometry analyses
Sacrifice and mononuclear cell-suspension preparation – Mice
were sacrificed via isoflurane inhalation and quickly perfused with
Ringer solution (Braun Medical, Emmenbruecke, Switzerland).
After removal of meningi, brain regions of interest were dissected
on ice. Lateral, third and fourth ventricle-choroid plexus were used.
Mononuclear single cell suspension was prepared according to
standard protocols (Suter et al., 2003). For cerebrum (whole brain
without cerebellum and choroid plexus), minced samples were
digested for 1 h at 37 C in HBSS containing 50 lg/ml DNase I
and 100 lg/ml collagenase/dispase (Roche, Rotkreuz, Switzerland).
The suspension was passed through a 100 lm Nylon mesh (Falcon,
BD Biosciences, Bedford, MA, USA), pelleted, resuspended in 30%
Percoll (Amersham, GE Healthcare, Uppsala Sweden) in HBSS and
centrifuged at 15,500 rpm for 30 min at 4 C. After eliminating
the myelin debris via aspiration, the mononuclear cell phase was
collected. Choroid plexus samples were enzymatically digested at
37 C for 30 min, passed through a 100 lmmesh, washed and used
directly. Spleens were minced in RPMI plus 5% FCS, digested with100 lg/ml collagenase–dispase and 50 lg/ml DNaseI for 20 min
at RT, passed through a 100 lm Nylon mesh, processed with ACK
lysis buffer, washed in HBSS and used for staining. Surface staining
– CNS-mononuclear cells and splenocytes were washed in FACS
buffer (HBSS, 2% FCS, 10 mM EDTA, 0.01% NaN3). After treatment
with an antibody against Fc receptor (anti-mouse CD16/32, TrueS-
tain FcX TM, BioLegend, san Diego, CA, USA), the cells were stained
for 15 min at 4 C with specific antibodies, washed and analysed.
Intracellular staining – Intracellular stainings were performed with
the eBioscience kit (n.72-5775, San Diego, CA, USA) according to
manufacturer’s instructions. DC panels – In each experiment we
included at least eight non-tg and eight tg mice. For the ArcAb
24-month-old experiment, a total of nine non-tg and ten ArcAb
APP-tg animal were used; we analysed the cerebrum from nine
tg and seven non-tg mice. Choroid plexuses were removed from
nine non-tg and ten tg animals. They were pooled (two-four/
sample), yielding a final n = 3 of bulk samples/genotype. The
spleens were dissected from four non-tg and four tg animals. A
multicolour FACS study was performedwith a BD LSR Fortessa ana-
lyzer. The panel for surface markers was: BV605-CD11c; FITC-
MHCII; PE-CY5-B220; PE-CY5.5-CD45; PE-CY7-CD11b; PE-TR-
CD80; APC-Cy7-CD86; APC-CD4; Alexa700-CD8a (all from eBio-
science, San Diego, CA, USA). In some experiments, PE-CD11c,
FITC-MHC-I and PE-MHC-II were used (from eBioscience, San
Diego, CA, USA). The panel for intracellular staining was: FITC-
MHCII; PE-CD11c; PE-CY5.5-CD45; APC-CD11b (all from eBio-
science, San Diego, CA, USA). A fixable live-dead dye to exclude
dead cells (Molecular Probes, Eugen, OR, USA) and compensation
beads to set the compensation matrix (eBioscience, San Diego,
CA, USA) were used. In some experiments, quantification beads
were used (AccuChek Counting beads, Life Technologies, Invitrogen
Corporation, MD, USA). Negative controls included isotype controls
and fluorescence-minus-one stainings. Splenocytes were used as
biological positive controls. T-cell panel – For 20-month-old ArcAb
mice, we analysed six non-tg and seven tg mice. Whole brains and
splenocytes from each mouse were stained for both surface and
intracellular markers. For cytokine detection, the cells were re-
stimulated in vitro at 37 C with PMA (107 M) and ionomycin
(1 lg/ml) in the presence of GolgiPlug (BD Bioscience, Bedford,
MA, USA). The panel used was: Surface: PE-CD45, Alexa700-CD8
(eBioscience, San Diego, CA, USA), APC-Cy7.7-CD4 (from BioLegend,
San Diego, CA, USA); intracellular: PE-CY5-FoxP3, Pacific-Blue-
IFNc, APC-IL10 (eBioscience, San Diego, CA, USA), PE.CY7-IL17A
(from BioLegend, San Diego, CA, USA), TNFa-FITC (eBioscience,
San Diego, CA, USA), Ki67-PE-TR (BioLegend, San Diego, CA, USA).
Live-dead dye and compensation beads were used (see above).
Counting beads (AccuChek Counting beads, Life Technologies,
Invitrogen Corporation, MD, USA) were added to CNS samples. Five
millions splenocytes were stained from each animal (measured via
Neubauer chamber and Coulter counter). Controls included
unstained CNS samples and single stained splenocytes. All samples
were acquired and analysed blinded to genotype. Definitions of cells
of the myeloid lineage – Microglia were defined as CD45intCD11b+
cells, while CD45hiCD11b+ cells were considered as periphery-
derived CNS myeloid cells (‘‘myeloid cells”). Conventional myeloid
DCs (cDCs) were defined as CD45+CD11c+CD11b+MHC-II+, as previ-
ously published (Hesske et al., 2010) and in accordance with a
recently proposed classification (Guilliams et al., 2014).
2.4. Bright-field immunohistochemistry
CD3, CD4, CD8, MHC-II – Mice were anesthetised via ketamine–
xylazine injection (10 ml/g bw) and quickly perfused with PBS. The
brains were dissected on ice and fixed in 4% paraformaldehyde
(granular, n.19210 Electron Microscopy Science) for 24 h (or 6 h
for detection of CD4 and CD8) and cryoprotected in 30% sucrose.
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and goat sera O/N, followed by treatment with avidin biotin block-
ing kit (Vectorlabs, SP2001, Burlingame, CA, USA). The primary
antibodies were incubated O/N at 4 C followed by 1 h incubation
with 1:200 biotinylated secondary antibody in 10% sera. The ABC
kit (Vector, PK6100 Standard, Burlingame, CA, USA) was used
according to manufacturer’s instructions. The staining was
revealed using nickel-enhanced DAB (n.1855910, Thermo Fisher,
Rockford, IL, USA). Haematoxylin counterstaining was performed
using Mayer’s hemalum solution (T865, Roth GmbH, Karlsruhe,
Germany). Negative controls included omission of primary anti-
body and RAG2ko mouse model. Positive controls were spleen
and liver tissue. VCAM1–ICAM1 – Mice were anesthetised via keta-
mine–xylazine injection (10 ml/g bw) and perfused with 1%
paraformaldehyde in PBS, pH 7.4; their brains removed, embedded
in Jung tissue freezing medium (Leica Microsystems, Nussloch,
Germany) and frozen in a dry ice/isopentane bath. Cryostat sec-
tions (6 lm) were fixed in 20 C acetone and stained using a
three-step immunoperoxidase staining kit (Vector).
2.5. Quantification CD3+ T-cell density
Per each animal, two whole sections corresponding to bregma
0.70 (for cortical density) and three sections corresponding to
bregma 0.70, 1.94, 3.16 (for total density) were stained with
anti-CD3 antibody as described above. Bright-field microscopy
images were acquired using a Leica DM4000B microscope (Leica,
Wetzlar, Germany) equipped with an Olympus DP71 digital cam-
era (Olympus, Volketswil, Switzerland). The number of CD3+ T-
cells was quantified in live mode using the meander tool of the
newCAST module of the Visiopharm software (Visiopharm,
HØrsholm, Denmark). For measurement of total CD3+ density, a
region of interest (ROI) was drawn around each section. For cortical
measurements, a ROI including somatosensory (S1BF, S1FL and
S1HL regions), motor cortex 1 and 2 and cingulate cortex was
drawn (see also Supplementary Fig. 1B). The automatic stage was
set to randomlymove within the ROI, sampling 50% of the ROI area.
On average, 15 images were quantified per ROI. CD3+ T-cells were
counted by the experimenter blind to the origin of the samples; the
numbers of counted elements and ROI size were automatically
recorded by the software. Counts were normalised to the size of
the respective ROI/2 and densities averaged across the sections
yielding one value per animal. All samples were acquired and anal-
ysed blinded to genotype.
2.6. Prussian Blue staining and quantification
Prussian Blue staining was performed on CD3-stained sections
(3/animal, corresponding to bregma 0.70, 1.94, 3.16) by incu-
bation with 1:1 solution of HCl 2% and 2% potassium ferrocyanide
trihydrate (K4[Fe(CN)]63H2O, Sigma-Aldrich, St Louis, MO, USA) in
distilled water. Images were acquired using a Leica DM4000B
microscope (Leica, Wetzlar, Germany) equipped with an Olympus
DP71 digital camera (Olympus, Volketswil, Switzerland). The num-
ber of CD3+ T-cells and Prussian Blue deposits was quantified in
live mode using the meander tool of the newCAST module of the
Visiopharm software (Visiopharm, Hørsholm, Denmark). A region
of interest (ROI) was drawn around each section. The automatic
stage was set to randomly move within the ROI, sampling 50% of
the ROI area. On average, 15 images were quantified per ROI. Total
CD3+ T-cells, total Prussian Blue deposits and Prussian Blue –
associated-CD3+ T-cells (either directly contacting the microhaem-
orrhage or within a radius of 10 lm from it) were counted in each
image by the experimenter blind to the origin of the samples.
Numbers of counted elements and ROI size were automatically
recorded by the software. Counts were normalised to the size ofthe respective ROI/2 and densities averaged across the three sec-
tions yielding one value per animal. All samples were acquired
and analysed blinded to genotype.
2.7. Immunofluorescence on mouse tissue
The free-floating sections were blocked for 1 h at RT in 10% sera
and incubated O/N with the proper primary antibody. The next day
the sections were incubated with the appropriate secondary anti-
body for 2 h. Sudan Black B (#199664, Sigma-Aldrich, St Louis,
MO, USA; 0.1% solution in 70% ethanol) was applied to eliminate
lipofuscin autofluorescence. DAPI was used as counterstaining
agent.
2.8. Thioflavin staining
The sections were treated with Thioflavin S (0.1% solution in
50% ethanol, T1892, Sigma-Aldrich, St Louis, MO, USA) for 5 min.
2.9. Extravasation study, correlation CD3+ T-cells-amyloid fractional
area and amyloid-CD3+ T-cell association study
Eight tg and seven non-tg ArcAbmice aged 15 months were sac-
rificed via isoflurane inhalation. Non-perfused brains were fixed in
4% paraformaldehyde for 12 h and cryoprotected in 30% sucrose for
30 h. Hundred micrometre-thick free-floating sections were
washed in Trizma-buffered saline containing 0.2% Triton X-100
(TBS-T, pH 7.4), treated with proteinase K antigen retrieval for
10 min at 37 C, followed by immuno-blocking in 10% donkey
serum in TBS-T for 1 h at RT. The sections were subsequently incu-
bated with rat anti-mouse CD3, rabbit anti-pan laminin, and
mouse anti-Ab antibody for 48 h at 4 C, followed by washing in
TBS-T and incubation in fluorescently tagged secondary antibodies
(donkey anti-rat-Cy3, donkey anti-rabbit-FITC, and donkey anti-
mouse-Cy5, Jackson Immunoresearch Labs, West Grove, PA, USA)
for 24 h at 4 C. Confocal microscopy images were acquired from
the cortex (forelimb and barrel field somatosensory region, cingu-
late cortex 1 and 2, and the primary visual cortex), hippocampus
(granular layer of the dentate gyrus and the cornu ammonis 1, 2,
and 3), and the corpus callosum of each mouse brain using a Leica
SP8 confocal microscope fitted with a 20 objective (Leica, Wet-
zlar, Germany) (see also Supplementary Fig. 1B for sampling).
The acquired images of each mouse were combined in Z-
projected image stacks in the ImageJ imaging software (National
Institutes of Health, Bethesda, ML, USA). All samples were acquired
and analysed blinded to genotype. Quantification of infiltrating ver-
sus intravascular T-cells: Total, infiltrating and intravascular CD3+ T-
cells were counted in the entire Z-stack (80 lm) and normalised to
the vessel density (lm3) in each brain section. Correlation infiltrat-
ing T-cells-amyloid fractional area: The number of extravasated
CD3+ T-cells and the area covered by 6E10-positive Ab plaques
was quantified using a semi-automatic Matlab script generated
in-house. The Ab/6E10-Cy5 and CD3-Cy3 confocal image stacks
were maximum-projected, converted to an 8-bits (grey-scale) for-
mat and thresholded. The number of CD3- and Ab/6E10-positive
hits was calculated by implementing Matlab’s ‘‘regionprops” tool
code in the script. CD3+ T-cells were calculated as counts and the
Ab/6E10-positive hits as fractions of the total image size. Quantifi-
cation of amyloid b and non-amyloid b-associated infiltrating CD3+ T-
cells: Quantification of infiltrating non-Ab-, parenchymal Ab
plaque- and CAA-associated CD3+ T-cells was performed on confo-
cal z-stack images of 100-lm thick mouse brain sections stained
for pan-laminin, CD3 and Ab. Areas with xyz dimensions of
1 mm  1 mm  100 lm were quantified within the brain areas
of interest. CD3+ T-cells within a 10-lm perimeter around the
outer edge of a parenchymal Ab plaque or vascular Abwere consid-
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did not fulfil these spatial distribution criteria were considered
non-Ab-associated.
2.10. Antibodies immunohistochemistry
For the detection of CD3 we used the clone KT3 (rat anti-mouse,
MCA 500GA, AbD Serotec, Kidlington, UK) and 145-2C11 from BD
Bioscience (Armenian-hamster anti-mouse CD3, #553058, Bed-
ford, MA, USA). Anti-CD4 and CD8 antibodies were from BD Bio-
science (rat anti-mouse CD4, clone GK1.5, #553727 and rat anti-
mouse CD8, clone 53-6.7, #553027, Bedford, MA, USA). Rabbit
anti-mouse pan laminin was from Sigma-Aldrich (L9393, St Louis,
MO, USA). For vascular adhesion molecules the primary antibodies
employed were: rat anti-mouse VCAM1 (clone 2A11.12), rat anti-
mouse ICAM1 (clone 25ZC7), rat anti human CD44 (clone 9B5)
was used as IgG control (Enzmann et al., 2013). For MHC-II detec-
tion we used the purified 2G9 clone from BD Bioscience (rat anti-
mouse class I-A/I-E, #553621, Bedford, MA, USA). The clone SP6
(RM-9106-S0, Thermo Fisher, Rockford, IL, USA) was used to detect
Ki67. For detection of MHC-I we used a rat anti-mouse antibody
from BMA biomedicals (T2105, Augst, Switzerland). Biotinylated
goat anti-mouse, – rabbit, and -Armenian hamster and donkey
anti-mouse, -rabbit, -guinea-pig or -rat conjugated with Cy3 or
DyeLight were from Jackson Immunoresearch Labs (West Grove,
PA, USA).
2.11. Statistical analysis
Data are presented as the mean ± S.E.M. Statistical analysis was
performed using the GraphPad Prism software (LaJolla, CA, USA).
Two-group comparisons were performed using two-tailed Stu-
dent’s t-test; Welsh’s correction was used in case of unequal vari-
ances. Multiple-group comparisons were performed with ANOVA
or 2-way-ANOVA, using the Bonferroni post-hoc test. Alpha level
to determine significance was set at p < 0.05.3. Results
3.1. Increased CD3+ T-cell occurrence in ArcAbmouse brains compared
to non-tg littermates
In order to study the effect of cerebral amyloidosis on T-cell
infiltration of brain, we have assessed the occurrence of CD3+ T-
cells via immunohistochemistry in 12- and 22–24-month-old
ArcAb mice as compared to age-matched, non-tg littermates.
CD3+ T-cells were only rarely observed in non-tg mice younger
than 11 month-old, mostly localised at expected sites of immune
surveillance such as the CP stroma and the meninges (data not
shown). In contrast, aged (12- and in 22–24-month-old) non-tg
mice consistently displayed CD3+ T-cell invasion in periventricular
areas, in white matter bundles (such as the corpus callosum, inter-
nal and external capsulae, fimbria and fornix) and in the rostro-
migratorial stream (Fig. 1A). The grey matter of aged non-tg mice
was largely devoid of T-cells, with the exception of small number
of cells in striatum and hippocampus. Quantification of CD3+ T-
cells revealed significantly increased total CD3+ T-cell density in
brains from 22–24-compared to 12-month-old non-tg mice
(Fig. 1C).
As opposed to age-matched non-tg littermates, several CD3+ T-
cells were present throughout the grey matter of cerebral cortex of
aged ArcAb mice (Fig. 1B). The CD3+ T-cells appeared both clus-
tered and dispersed in the neuropil, with CD8+ being the predom-
inant T-cell subtype. Both the total (i.e. measured in white and grey
matter from the whole brain section) and the cortical (i.e. mea-sured exclusively in grey matter of cerebral cortex) densities of
brain CD3+ T-cells were found to be significantly up-regulated at
22–24-months of age in ArcAb mice compared to non-tg controls
(Fig. 1C and D). At 12-months of age only the cortical CD3+ T-cell
density was increased in ArcAb mice compared to littermate con-
trols, suggesting a local redistribution of the cells (Fig. 1E).
Flow-cytometry analysis of ex vivo isolated mononuclear cells
derived fromwhole brains (thus combining grey matter- and white
matter-associated cells) revealed that CD8+ but not CD4+ T-cell
numbers were increased in ArcAb mice, reaching significance at
the 24-month-old time-point (Fig. 1E). Importantly, no significant
difference in splenic T-cell counts was found between non-tg and
ArcAb mice. Hence, compared to non-tg controls, ArcAb mice har-
bour increased cerebral CD3+CD8+ T-cells, which are focally accu-
mulated in grey matter areas at 12-months of age and become
wide-spread at 22–24-months of age.
3.2. CD3+ T-cells infiltrate the brain parenchyma of ArcAb mice
To determine whether the CD3+ T-cells observed in ArcAb
mouse brains had migrated into the parenchyma or whether they
were trapped in the perivascular space, 100-lm-thick brain sec-
tions from non-perfused 15-month-old ArcAb and non-tg litter-
mates were double-labelled for CD3 and pan-laminin, followed
by confocal imaging and 3D reconstruction (Fig. 2A). This allowed
us to quantify in each section both infiltrating (i.e. beyond the pan-
laminin layer, such as cells 2–3 in Fig. 2B) and intravascular CD3+
T-cells.
Compared to non-tg littermate controls, ArcAb brains displayed
significantly more infiltrating, but not intravascular, CD3+ T-cells in
all cortical areas examined, as well as in the hippocampal CA1 field
and in the corpus callosum (Table 1). The increased numbers of
infiltrating cells was not due to hyper-vascularization in ArcAb
mice, since vessel density was not significantly different between
genotypes (data not shown). Hence, ArcAb mice brains were
invaded by CD3+ T-cells, which had crossed the glia limitans,
resided in the parenchyma and closely associated with CNS-
resident cells such as astrocytes (GFAP staining, Fig. 2D), neurons
(NeuN staining, Fig. 2E) and microglial/myeloid cells (Iba-1 stain-
ing, Fig. 2F) as revealed by confocal microscopy. Furthermore, we
have observed that, on average, 77% of total cortical CD3+ T-cells
detected in ArcAb cerebral cortex were infiltrating, as opposed to
35% in non-tg littermate controls (Fig. 2C), indicating a shift in
the intravascular versus parenchymal T-cell pool in ArcAb brains.
3.3. Relationship between cerebral amyloidosis and CD3+ T-cells in
ArcAb mice
The increased frequency of infiltrating CD3+ T-cells (Fig. 2C)
suggested the presence of a T-cell attraction- and/or retention-
factor in brains from ArcAb mice. To ascertain whether cerebral
beta-amyloidosis was the cause of T-cell attraction/retention, we
compared the occurrence of CD3+ T-cells between several, inde-
pendent amyloid-depositing tg models, and the E22DAb mice,
which over-express amyloid precursor protein (APP) but harbour
a pathology limited to intracellular Ab and leptomeningeal amyloi-
dosis (Kulic et al., 2012) (Fig 3A, upper panel). While CD3+ T-cells
infiltrated the grey matter of all amyloid-depositing mouse brains
(Fig. 3A, lower panel), no CD3+ T-cells were detected in the grey
matter of the E22DAb mice. These results suggested that extracel-
lular, parenchymal amyloidosis is required for T-cell invasion.
To further examine this possibility, we studied the relationship
between CD3+ T-cells and 6E10-positive amyloid deposits in brains
of 15-month-old ArcAb mice, which are heavily burdened by amy-
loid pathology consisting of both cerebral amyloid angiopathy
(CAA)- and parenchymal plaques. Here, we found a significant cor-
Fig. 1. Increased occurrence of CD3+ T-cells in brains of aged ArcAbmice. (A) Representative micrographs illustrating typical white-matter associated CD3+ T-cell distribution
observed in non-tg mice of 12- and 24-months of age (upper and lower panel, respectively). Arrows indicate CD3+ T-cells lining the tissue connecting fimbria to CP. cc: corpus
callosum, CP: choroid plexus, CPu: Caudatum Putamen, e: ependyma, ec: external capsula, hf: hippocampal fissure, lv: lateral ventricle, rms: rostro migratorial stream, ctx:
cortex, f: fimbria, th: thalamus. (B) Representative micrographs illustrating typical grey-matter CD3+ T-cell distribution in ArcAbmice of 12- and 24-months of age (upper and
lower panel, respectively; CD4 and CD8 staining are also shown). Arrow points to a cluster of CD3+ T-cells in the proximity of the CP at the ventral horn of the lateral ventricles
(arrow). s: subiculum, ctx: cortex. (C) Quantification of CD3+ T-cell density, as detected via immunohistochemistry in whole sections from 12 and 22-month-old ArcAb mice
and non-tg littermate controls (n = 5–6 per group, *p < 0.05, ***p < 0.001, 2-way-ANOVA followed by Bonferroni post-hoc test; effect of age, genotype and interaction:
p < 0.001). (D) Quantification of CD3+ T-cell density, as detected via immunohistochemistry in grey matter of cerebral cortex (see Supplementary Fig. 1B for exact sampling
area) from 12- and 22-month-old ArcAbmice and non-tg littermate controls (n = 5–6 per group; *p < 0.05, **p < 0.01, ***p < 0.001, 2-way-ANOVA followed by Bonferroni post-
hoc test; effect of age: p < 0.01, effect of genotype: p < 0.001, interaction: p < 0.01). (E) Quantification of absolute numbers of lymphocytes via multicolour flow-cytometry
analysis of brain-derived mononuclear cell suspensions from 12- and 24-month-old ArcAb and non-tg littermate controls (n = 6–8 per group, *p < 0.05, Student’s t-test). (F)
Quantification of absolute numbers of lymphocytes via multicolour flow-cytometry in spleen-derived mononuclear cell suspensions from 24-month-old ArcAb and non-tg
littermate controls.
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Fig. 2. T-cells infiltrate the brain parenchyma of ArcAb mice. (A) Z-stack maximal projection of a representative pan-laminin/CD3 double labelling on non-perfused 15-
month-old ArcAbmouse brain. Scale bar: 50 lm. (B) Z-stack maximal projection and three individual stacks of a pan-laminin/CD3 double labelling on an ArcAbmouse brain.
Examples of perivascular (1), juxtavascular (2) and parenchymal (3) T-cells are shown. Scale bar: 20 lm. (C) Quantification of infiltrated CD3+ T-cells from brains of non-
perfused 15-month-old ArcAbmice (n = 8) and non-tg littermate controls (n = 7) in somatosensory and cingulate cortex. Data are expressed as percentage over total number
of CD3+ T-cells. (*p < 0.05, Student’s t-test). (D–F) Representative micrographs illustrating the relationship between CD3+ T-cells and astrocytes (GFAP staining, D), neurons
(NeuN staining, E) and microglial cells (Iba-1 staining, F) in cerebral cortex of aged ArcAb mice. Z-stack maximal projections images are shown. Scale bars: 20 lm.
Table 1
Quantification of intravascular and infiltrated CD3+ T-cells in brains of 15-month-old
ArcAb mice (n = 8) and non-tg littermates (n = 7).
Brain area Intravascular CD3+ T-cells
(n/field ± S.E.M.)
Infiltrating CD3+ T-cells
(n/field ± S.E.M.)
Non-tg ArcAb Non-tg ArcAb
GrDG 2.57 ± 0.81 1.63 ± 0.56 4.71 ± 1.21 12 ± 4.78
CA1 1.83 ± 0.69 2.13 ± 0.93 2.83 ± 0.61 9.25 ± 2.30⁄⁄
CA2, CA3 2.830.81 1 ± 0.38 4.17 ± 0.94 5.38 ± 1.19
Corp call 5.86 ± 1.68 4.63 ± 1.25 6 ± 2.27 32 ± 9.06⁄⁄
S1FL 0.71 ± 0.36 2.130.55 0.57 ± 0.30 11.88 ± 4.02⁄⁄
S1BF 0.67 ± 0.46 1.75 ± 1.02 0.17 ± 0.15 16.5 ± 5.79⁄⁄
Cg1, Cg2 3.14 ± 1.56 2.880.46 1.290.75 7.13 ± 2.33⁄⁄
V1 0.33 ± 0.20 1 ± 0.33 0.67 ± 0.20 8.75 ± 3.93⁄
GrDG = granular layer of the dentate gyrus, CA1, 2, and 3 = corpus ammonis 1, 2,
and 3, resp., Corp call = corpus callosum, S1FL = somatosensory cortex, front leg,
S1BF = somatosensory cortex, barrel field, Cg1, Cg2 = cingulate cortex 1 and 2,
V1 = visual cortex 1.
*p < 0.05; **p < 0.01, Mann–Whitney t-test (compared to non-tg).
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area (including both parenchymal plaques and CAA) in cerebral
cortex and hippocampus. (Fig. 3B, p < 0.01, Pearson’s correlation
analysis). However, microscopic examination revealed that only
34% of the total CD3+ T-cells detected were spatially associated
with Ab, and of these Ab-associated cells, the majority (70%)
accompanied CAA rather than parenchymal plaques (Fig. 3C–E).
Taken together, these data suggest that extracellular amyloid
deposition promotes T-cell infiltration; however, the effect is likely
to be indirect since CD3+ T-cells are not consistently associated
with amyloid deposits.
3.4. Possible mechanisms of CD3+ T-cell brain infiltration
We next sought to elucidate the mechanism of CD3+ T-cell infil-
tration in ArcAb mice brains. Since T-cells occasionally decorated
Ab-laden vessels, we reasoned that microhemorrhages, whichoften accompany CAA, could be the cause of T-cell invasion. The
spatial association between CD3+ T-cells and Prussian Blue (PB)-
positive microhemorrhages was examined in brains from 12- and
22-month-old ArcAb via immunohistochemistry. PB-associated
CD3+ T-cells were only occasionally observed in 12-month-old tg
mice (in 1 out of 5 mice), while they were consistently found in
22-month-old mice (in 4 out of 5 mice, Fig. 4A lower panel). How-
ever, the PB-associated CD3+ T-cells represented less than 2% of the
total CD3+ T-cells detected (Fig. 4B); the remaining CD3+ T-cells
resided several hundred micrometres away from PB deposits
(Fig. 4A, upper panel). Furthermore, there was no correlation
between the numbers of PB deposits and CD3+ T-cells in neither
12- nor 22-month-old brains (Fig. 4C). Similar results were
obtained in the APP-PS1-dE9 and Tg2576 APP-tg models (data
not shown). Thus, passive leucocyte extravasation was observed
along with brain microhaemmorhages in aged ArcAb mice; how-
ever microhaemorrhaging was not likely to be the main cause of
T-cell invasion.
On the other hand, infiltration of T-cells could involve
endothelial cell activation via expression of endothelial cell adhe-
sion molecules. Therefore, ICAM-1 and VCAM-1 levels were inves-
tigated by immunohistochemistry in 20-24-month-old ArcAb
mice and non-tg littermate controls. Both adhesion molecules
were found to be up-regulated in cortical brain areas and hip-
pocampus of ArcAb mice compared to non-tg controls (Fig. 4D).
Examination at high magnification revealed a distinctive plaque-
associated (asterisk) and vessels immunoreactivity (including
large and small vessels) in ArcAb mice (Fig. 4D inserts). Such
expression was pathology-specific, as it was not observed in
age-matched non-tg littermate controls (Fig. 4D) but was consis-
tently found in amyloid-burdened brain areas of all APP-tg mod-
els examined (Supplementary Fig. 2B). Furthermore, no up-
regulation of VCAM-1 and ICAM-1 was detected in the low-
pathology cerebellum of the same mice (Supplementary
Fig. 2A), which is also devoid of T-cell infiltration (Supplementary
Fig. 1A). These results suggest that endothelial activation drives
CD3+ T-cell infiltration in APP-tg mice brains.
Fig. 3. Relationship between infiltrating CD3+ T-cells and cerebral amyloidosis. (A) Representative micrographs illustrating CD3+ T-cells and Thioflavin-positive amyloid
deposits observed in 20–24 month old wild type and several, independent APP-tg mice. Brain parenchymal T-cells were observed in all amyloid-depositing mice models
examined but not in the amyloid-free E22DAb. Scale bar Thioflavin S: 300 lm, CD3: 80 lm. (B) Correlation between CD3+ T-cell numbers and the fractional area occupied by
beta-amyloid (as detected via 6E10 antibody) in cerebral cortex and hippocampus from 15 month-old ArcAb mice (n = 8, p < 0.01, Pearson’s correlation). (C and D)
Representative pan-laminin/CD3/6E10 triple-labelling in the cerebral cortex of a non-perfused 15-month-old ArcAb mouse (images are shown as Z-stack maximal
projections). Arrowheads and asterisk in (C) indicate non-Ab-associated and a CAA-associated cell, respectively. Arrow-heads in (D) point to CAA-associated CD3+ T-cells,
while the arrow points to a parenchymal Ab-plaque with an associated CD3+ T-cells (asterisk). Scale bar = 50 lm. (E) Quantification of the frequency of non-Ab-associated and
Ab-associated CD3+ T-cells in brains of 15-month-old ArcAb. Within the Ab-associated CD3+ T-cells, the proportion of CAA- versus parenchymal plaque- (PP) associated CD3+
T-cells is shown (average values of n = 8 mice examined).
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activity and low IFN-c expression
Having detected numerous infiltrating CD3+ T-cells in brains of
ArcAb mice, we asked whether these cells were proliferating
locally into effector, IFN-c-producing cells.
CD3+ T-cells from 12- (Fig. 5A) and 24-month-old (Fig. 5B)
ArcAbmice did not show detectable expression of the proliferation
marker Ki67 via confocal microscopy, even when clustered around
parenchymal amyloid plaques (Fig. 5A). The Ki67 proliferating cells
observed were mostly myeloid, CD68-positive cells (data not
shown). The expression levels of Ki67 were further investigated
via flow-cytometry on ex-vivo isolated CD4+ and CD8+ T-cells from
20- to 24-month-old mice; no increase in either the frequency of
Ki67-expressing cells or their fluorescence intensity in the Ki67
channel was observed in ArcAb mice compared to non-tg litter-
mates (Fig. 5C).
Next, we analysed via flow-cytometry the production of the
effector cytokine IFN-c by brain-derived CD4+ and CD8+ T-cellsfrom 20 month-old ArcAb and non-tg littermates. We observed a
decreased percentage of IFN-c producing cells in ArcAb mice, both
in the CD4+ and CD8+ T-cell subsets (Fig. 5D and E). The propor-
tional decrease in IFN-c-producing cells was due to an increase
in the absolute numbers of the IFN-c-negative population
(Fig. 5F). Furthermore, IFN-c expressing cells from ArcAb mice
showed lower fluorescence intensity (FI) in the IFN-c channel, indi-
cating lower levels of expression compared to littermate controls
(Fig. 5G). The frequency and absolute numbers of CD4+ and CD8+
T-cells expressing IL-10, IL-17 and FoxP3 did not differ across the
genotypes (Supplementary Fig. 5) and no significant differences
in IFN-c-producing cells were found in spleens of ArcAbmice com-
pared to littermate controls (Fig. 5H). Decreased frequency of IFN-
c-expressing brain-derived CD4+ and CD8+ T-cells was also
observed in the APP-PS1-dE9 model of AD-like amyloidosis (Sup-
plementary Fig. 3B). Hence, infiltrating T-cells did not proliferate
locally and did not display an effector phenotype in ArcAb brains,
suggesting low activation state in the presence of cerebral
amyloidosis.
Fig. 4. Mechanisms of CD3+ T-cell infiltration in ArcAb mice brains. (A) Representative Prussian Blue (PB)/CD3 staining on a section from a 22-month-old ArcAb mouse. The
upper image illustrates the occurrence of a PB-independent cluster of CD3+ T-cells in cerebral cortex (inset shows a high magnification view of the two framed CD3+ T-cells).
Asterisks in the lower image indicate PB-associated CD3+ T-cells. Scale bar: 80 lm. (B) Percentage of Prussian Blue (PB)-associated CD3+ T-cells over total CD3+ T-cells
detected in 12- and 22-month-old ArcAbmice. Absolute numbers of PB-associated/total CD3+ T-cells are indicated. (C) Correlation between Prussian Blue deposit and CD3+ T-
cell densities in brains of 12- and 22-month-old ArcAb mice. (Spearman’s correlation analysis, not significant.) (D) Representative micrographs illustrating the staining for
endothelial adhesion molecules VCAM-1 and ICAM-1 in brains of 20 month-old non-tg and ArcAb mice. Asterisk indicates typical peri-plaque staining observed in ArcAb
mice. Scale bars: 200 lm, insets: 25 lm.
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phenotype
T-cell activation depends on antigen-presentation by the MHC
class I (MHC-I) and MHC class II (MHC-II) molecules at the surfaceof mature APCs, such as dendritic cells (DCs) (Banchereau and
Steinman, 1998). In contrast to mature APCs, which express high
surface levels of MHC-II and are potent inducers of T-cell priming
and activation, immature APCs -characterised by low surface levels
of MHC-II expression and accumulation of MHC-II within intracel-
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and Schuler, 2002)). We therefore analysed MHC-II surface expres-
sion by flow-cytometry on ex-vivo isolated mononuclear cells
derived from cerebra of 20 month-old ArcAb and non-tg litter-
mates (Fig. 6). Since B cells were virtually undetectable in brains
of both genotypes, we focused on cells of the myeloid lineage. To
distinguish resident microglia from other periphery-derived mye-
loid cells, we have taken advantage of their well-known differen-
tial surface expression of the markers CD45 and CD11b (Prinzet al., 2011; Greter et al., 2015). This approach allowed us to clearly
identify microglial cells (CD11b+CD45int) and periphery-derived
CNS ‘‘myeloid cells” (CD11b+CD45hi, e.g. perivascular and lep-
tomeningeal DCs and macrophages, Fig. 6A). The frequency of both
myeloid populations was significantly increased in the ArcAb mice
(Fig. 6A and C), with signs of microglial activation (increased
expression of CD45 and CD11c, Fig. 6D and data not shown) com-
pared to littermate controls.
We investigated the surface expression of MHC-II on microglia
(CD11b+CD45int) and bona-fide DCs (MHC-II+CD11c+CD11b+CD45hi,
including perivascular and letpomeningeal DCs) in our samples.
MHC-II+ microglial cells were hardly detectable in non-tg cerebra
(1% of all microglial cells, Fig. 6E), and displayed only intermediate
levels of MHC-II expression (Fig. 6B), in agreement with the notion
of microglial cells being immature APCs (Carson et al., 1998; Aloisi
et al., 2000a). In contrast, cerebrum-derived DCs, even though rare,
expressed high levels of MHC-II (Fig. 6B), consistent with the
known mature APCs phenotype of perivascular and let-
pomeningeal DCs (Colton, 2013).
ArcAb cerebra harboured an overall increased frequency ofMHC-
II+ microglial cells and DCs compared to non-tg littermates (Fig. 6E).
However, the MHC-II fluorescence intensity was significantly lower
inArcAb samples compared to controls (Fig. 6F). In fact, only the pro-
portion of MHC-IIint microglia and MHC-IIint DCs was increased in
ArcAb mice samples (Fig. 6G). On the other hand, the frequency of
MHC-IIhi cells was decreased in ArcAb samples (as in the case of
microglial cells) or unchanged (in the DCs subset) compared to
non-tg littermate controls (Fig. 6G). No increase in CD80 and
CD86, co-stimulatory molecules required for T-cell activation, was
observed in brain-derived APCs from ArcAb samples (Supplemen-
tary Fig. 4B–D). Unchanged MHC-IIhi cells (frequency and absolute
numbers of both microglial and DCs) and increased frequency of
MHC-IIint were observed also in the APP-PS1-dE9 model of AD-like
amyloidosis (Supplementary Fig. 3E–I and Supplementary Table 1).
Taken together, the results suggested that APCs acquire an imma-
ture phenotype in the presence of cerebral amyloidosis.3.7. Accumulation of intracellular MHC-II in ArcAb brains
If APCs in ArcAb brains display an immature phenotype, they
should accumulate MHC-II in intracellular compartments. To test
this, we measured total (surface plus intracellular) MHC-II expres-
sion in mononuclear cells derived from the same samples. This
analysis confirmed a significant increase in MHC-II-expressing cell
numbers (Fig. 6H and I). In contrast to the reduced surface expres-
sion levels (Fig. 6F) we found an unchanged expression of total
MHC-II in microglia (Fig. 6J) indicating an increase in intracellular3
Fig. 5. Lack of proliferation and low pro-inflammatory cytokine production in brain
derived T-cells from ArcAb mice. (A and B) Representative micrographs illustrating
a CD3/Ki67double staining on a 12- (A) and 24-month-old (B) ArcAbmouse cerebral
cortex. Scale bars: 50 lm. (C) Flow-cytometry analysis of Ki67 expression on CD4-
and CD8-positive lymphocytes subsets from 20- to 24-month old ArcAb mice and
non-tg control littermates (n = 4). Data are shown as percentage as well as
fluorescence intensity (FI) of Ki67 positive cells. (D) Representative dot-plots of
flow-cytometry stainings of brain-derived lymphocytes from a 20-month-old ArcAb
mouse and a littermate control. Mononuclear cells were obtained from brains and
stained for surface and intracellular markers of interest; CD4+ and CD8+ lympho-
cytes were gated from live CD45hi cells and within each compartment the
expression of IFN-c+ was examined. (E–G) Analysis of brain-derived CD4+ and
CD8+ T-cells from ArcAb mice (n = 7) as compared to aged-matched non-tg
littermates (n = 6). (E) Frequency of IFN-c+ cells (expressed as percentage of
positive cells over total cells of interest). (F) Quantification of absolute numbers of
IFN-c+CD8+ and IFN-cCD8+ cells. (G) Fluorescent intensity (FI, expressed as
geometric mean) of IFN-c staining on CD8+ and CD4+ cells. (H) Analysis of spleen-
derived CD4+ and CD8+ T-cell compartments. (*p < 0.05, **p < 0.01, ***p < 0.001,
Student’s t-test).
Fig. 6. Occurrence of immature APCs in cerebra of ArcAb brains. (A) Representative dot plots of flow-cytometry surface staining of live cells from 24 month-old non-tg and
ArcAb samples. Mononuclear cells were isolated from the cerebrum and stained for markers of interest, allowing the identification of microglial cells (CD11b+ CD45int) and
other infiltrating myeloid cells (CD11b+ CD45hi). (B) Analysis of MHC-II expression on MHC-II+ microglial cells and dendritic cells (DCs: MHC-II+ CD11c+ CD11b+ CD45hi) from
(A). (For details on gating see Supplementary Fig. 4A.) (C) Quantification of microglia and myeloid infiltrating cells in ArcAb cerebrum (Tg, n = 9) and non-tg controls (n = 7).
Data are expressed as frequency over live cells. (D) Fluorescence intensity (FI, expressed as geometric mean) of CD45 signal on microglial cells from A. (E–G) Quantification of
MHC-II+, MHC-IIint and MHC-IIhi microglia and DCs (from A and B) in ArcAb cerebra and non-tg control littermates. (E) Percentage of MHC-II+ cells over the cell population of
interest, i.e. microglia cells or myeloid cells. (F) Geometric mean of fluorescent intensity (FI) of MHC-II signal. (G) Frequency of MHC-IIhi and MHC-IIint cells over the cell
population of interest. (H–J) Representative dot-plot and quantification of flow-cytometry staining of total (intracellular plus surface) MHC-II on microglia and DCs. (I)
Frequency of MHC-II+ cells (expressed as percentage of positive cells over cell population of interest. (J) Fluorescence intensity (FI, expressed as geometric mean) of MHC-II+
cells. (K) Representative MHC-II staining from the cerebral cortex of a 20-month-old ArcAb and non-tg littermate acquired at the confocal microscopy with low (upper row,
scale bar: 100 lm) and high (lower row, scale bar: 10 lm) magnification. Arrows indicate typical diffuse and membrane-bound signal on MHC-II+ perivascular cells from non-
tg brain, while arrowheads point to peculiar intracellular MHC-II immunoreactivity in a Tg sample. Data are shown as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, Student’s
t-test. n.s. = not significant.
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Fig. 7. Loss of MHC-II expression at the choroid plexus of aged ArcAb mice. (A) Representative histograms of MHC-II flow-cytometry surface staining (red line) and
corresponding isotype control (shaded blue) on CP-derived dendritic cells (CP DCs, CD45hiCD11b+CD11c+) and splenic CD11b+CD11c+ conventional dendritic cell population
(cDCs) from 24 month-old ArcAb mice (n = 9) and aged-matched littermates (n = 7). (B) Quantification of frequency (expressed as percentage over CD11b+ cells) and
fluorescence intensity (FI, expressed as geometric mean) of the MHC-II+ populations gated in (A). Data are shown as mean ± SEM; *p < 0.05, **p < 0.01, Student’s T-test. (C)
Representative MHC-II staining in the CP of an aged ArcAbmouse and littermate control. Scale bar: 40 lm. (For interpretation of the references to colour in this figure legend,
the reader is referred to the web version of this article.)
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MHC-II was observed also in a second APP-tg model, the APP-PS1-
dE9 (Supplementary Fig. 3J).
We next sought to confirm our flow-cytometry data using con-
focal microscopy. As expected, we detected several intensely
labelled MHC-II+ cells in 20-month-old ArcAb mice brains, while
only few MHC-II-positive meningeal and perivascular cells were
observed in non-tg brains (Fig. 6K, upper row). When imaged at
high magnification, MHC-II+ cells from ArcAb mice harboured a
distinct and intense intracellular vesicle-like staining (Fig. 6K,
lower row, arrow-heads), as opposed to the diffuse and
membrane-bound signals observed in perivascular MHC-II+ cells
from non-tg brains (Fig. 6K, lower row, arrows). The vesicle-like
MHC-II staining was consistent with an intracellular accumulation
of MHC-II seen via flow-cytometry, and further supported the
notion of an immature phenotype of APCs in ArcAb brains.
3.8. Loss of antigen-presenting cells at the choroid plexus of ArcAb
mice
MHC-II expression was further analysed at the level of the
blood–CSF-barrier in the CP, where mature DCs responsible for
brain immune surveillance are known to reside (Colton, 2013;
Anandasabapathy et al., 2011).
Bona-fide DCs constituted up to 40% of the CD11b+CD45hi pop-
ulation, with high MHC-II-expression levels comparable to splenic
DCs (Fig. 7A and B). We found that choroid plexus-DCs (CP DCs)
from ArcAb of 20-months of age were less frequent and exhibited
lower MHC-II expression levels compared to age-matched non-tg
littermates (Fig. 7A and B). The reduction in MHC-II expression at
the CP, confirmed by immunohistochemistry (Fig. 7C), further indi-
cated low antigen-presentation in brains of ArcAb mice.
3.9. MHC-I up-regulation on brain-derived myeloid cells from ArcAb
mice
To complete our characterisation of brain-derived antigen pre-
senting cells in amyloid-burdened mice, we have assessed theexpression of MHC-I on brain myeloid cells via flow-cytometry
and confocal microscopy. For these studies we used 22–
25 month-old ArcAb mice, since this model presented with robust
infiltration of CD8+ T-cells as of 22 months of age.
The frequency of MHC-I-positive microglia and periphery-
derived myeloid cells was significantly increased in ArcAb mice
compared to aged-matched non-tg littermates (Fig. 8A and B),
while it was unchanged in the amyloid-free cerebellum from the
same mice (Fig. 8D). In addition, MHC-I expression was signifi-
cantly up-regulated on both microglial and other myeloid cells
derived from cerebrum, but not cerebellum, of ArcAb mice
(Fig. 8B and C). Confocal microscopy revealed strong MHC-I expres-
sion by perivascular Iba-1 positive cells in aged ArcAb mice
(Fig. 8C). Increased MHC-I expression at the perivascular sites
might support antigen-specific recruitment of CD8+ T-cells into
the brain parenchyma of ArcAb mice (Galea et al., 2007).4. Discussion
There is convincing evidence from pre-clinical, epidemiological
and genetic studies that the immune system plays a crucial role in
AD (Wyss-Coray and Rogers, 2012; International Genomics of
Alzheimer’s Disease and International Genomics of Alzheimer’s
Disease Consortium, 2015). A decreased phagocytic activity of
microglia due to chronic activation is currently regarded as the
main cause of defective Ab clearance from AD brains (Krabbe
et al., 2013; Hellwig et al., 2015). Whether lymphocytes and T-
cells in particular contribute to the immune dysfunction observed
in AD is not known. Even though infiltrating T-cells in brains of AD
patients have been consistently reported in the literature (Rogers
et al., 1988; Itagaki et al., 1988; Togo et al., 2002), comprehensive
examination of their localisation and activation state is lacking,
probably due to the low numbers of cells of interest in the post-
mortem brain specimens and the unsuitability of most samples
for ex vivo flow-cytometry analysis.
On the other hand, tg mice, which reproduce severe AD-like
cerebral amyloidosis, are the ideal tool to investigate the impact
of amyloid on T-cell migration and function in brain. To this aim,
Fig. 8. MHC-I up-regulation in ArcAb mice brain-derived myeloid cells. (A) Representative dot-plots of flow-cytometry staining of cerebrum-derived microglia and other
myeloid cells from a 23-month-old ArcAb mouse and an aged-matched non-tg littermate control. Cerebrum-derived mononuclear cells were stained for surface markers of
interest; CD11b+CD45int (microglial cells) and CD11b+CD45hi (periphery-derived myeloid cells) were gated from live cells and examined for MHC-I expression. ‘Control’
illustrates the fluorescence-minus-one staining, omitting the MHC-I antibody. (B) Quantification of the MHC-I-positive cells from the cerebrum of 23–25-month old ArcAb
mice and littermate controls, as gated in (A) (n = 4,5). Data are shown as percentages as well as fluorescence intensity (FI) of positive cells. (C) Representative confocal images
from a 22-month old ArcAb mouse brain section double-stained with Iba-1 and MHC-I antibodies. V: outline of a vessel. Asterisks indicate perivascular Iba-1-positive cells
expressing MHC-I. Arrow-heads point to MHC-I expression on the luminal surface of the endothelium. Scale-bar: 10 lm. (D) Quantification of the MHC-I-positive cells from
the cerebellum of 23–25-month old ArcAb mice and littermate controls (n = 4,5). Data are shown as percentages as well as fluorescence intensity (FI) of positive cells. (Data
are shown as mean ± SEM. **p < 0.01, ***p < 0.001, Student’s T-test).
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ArcAb mouse, which presents the advantage of harbouring abun-
dant parenchymal plaques and CAA as of 12-months of age
(Knobloch et al., 2007); subsequently, we have replicated our
observations in at least one additional APP-tg model.
Indeed, all APP-tg mice depositing cerebral amyloidosis repro-
duced the AD-like T-cell infiltration in brain. Infiltrating T-cells
were observed in amyloid-burdened areas of three APP-tg micemodels, independent of background, promoter used and of APP
overexpression; in fact, it was neither observed in the plaque-
free E22DAb mice (Fig. 3A) nor in systemic compartments
(Fig. 1F). No CD3+ T-cell was observed in RAG2-deficient APP-
PS1-dE9 mice lacking mature B and T-cells, thus confirming the
specificity of our technique (Supplementary Fig. 1C). The occur-
rence of brain infections that might explain the high CD3+ T-cell
numbers was excluded via a specific microbiological examination.
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the context of AD-like pathology. Taking advantage of APP-tg mod-
els, we have investigated the role of aging, CAA, parenchymal pla-
ques and vascular alterations in T-cell infiltration, as well as
obtained insights into their activation state.
We found that aging per se contributed to T-cell infiltration; in
fact, brain CD3+ T-cells were consistently detected in non-tg mice
as of 12-months of age and were significantly increased at 22–
24-compared to 12-month of age (Fig. 1A and C). However, in
agreement with previous reports (Stichel and Luebbert, 2007)
CD3+ T-cells were observed mostly in association with nervous
fibres in non-tg mice (possibly due to white matter lesions
described in older individuals (Maniega et al., 2015)), while cortical
areas were largely devoid of T-cell invasion. In contrast, APP-tg
mice were readily distinguishable from control mice by the pres-
ence of more numerous infiltrating CD3+ T-cells, localised at the
grey matter of all brain cortical areas examined (Fig. 1B–D). There-
fore, amyloid-dependent T-cell invasion was qualitatively and
quantitatively different from the age-dependent T-cell occurrence.
Our observations in APP-tg models would support the notion
that parenchymal amyloid causes brain T-cell invasion. Indeed,
we found a significant correlation between CD3+ T-cell numbers
and amyloid fractional area in ArcAb brains (Fig. 3B), while the
cerebellum of amyloid-depositing APP-tg mice (Supplementary
Fig. 1A) and the brains of E22DAb mice (Fig. 3A), which are devoid
of parenchymal amyloidosis, did not show invading CD3+ T-cells.
However, only a small fraction of infiltrating CD3+ T-cells observed
in 15-month old ArcAb brains was amyloid-associated (Fig. 3C–E),
similarly to previous observations (Jimenez et al., 2008). The above
results suggest that cerebral amyloid is necessary but not sufficient
for T-cell invasion, which is likely caused by further downstream
amyloid-mediated pathological events.
APP-tg mice and ArcAb in particular (Merlini et al., 2011) dis-
play micro bleeds and loss of BBB integrity, which could contribute
to T-cell invasion. We did not observe a physical association
between T-cells and micro-haemorrhages detected with PB
(Fig. 4A–C). Since PB reveals residual hemosiderin that has accu-
mulated 6 to 10 days after the occurrence of a micro bleed
(Koeppen et al., 1995), T-cells might have already migrated in
the parenchyma, explaining the lack of co-localisation. In this sce-
nario, the densities of PB deposits and T-cells should correlate,
even in the absence of direct spatial association. However, no such
correlation was found (Fig. 4B); furthermore, no infiltrating B cells
were detected (confirming (Rogers et al., 1988); data not shown),
suggesting that physical BBB damage was not the cause of global
lymphocyte extravasation. On the other hand, T-cell invasion in
APP-tg brains was likely to be an active process relying on the
interaction between endothelial adhesion molecules ICAM-1 and
VCAM-1 and their cognate ligands leucocytes function-associated
antigen (LFA)-1 and a4b1-integrin expressed on leucocytes
(Engelhardt and Ransohoff, 2012). In fact, we observed strong up-
regulation of endothelial adhesion molecules VCAM-1 and ICAM-1
in APP-tg mice brains areas, such as cerebral cortex and hippocam-
pus, which are invaded by CD3+ T-cells (Fig. 4D and Supplementary
Fig. 2B), while no up-regulation was observed in cerebellum, an
area spared by T-cell invasion (Supplementary Figs. 1A and 2A).
Indeed increased LFA-1 ligand expression has been reported on
AD brain-infiltrating T-cells (Togo et al., 2002). The cause of
VCAM-1 and ICAM-1 up-regulation in amyloid-burdened areas is
currently unknown; however, soluble inflammatory cytokines
such as TNF, IFN-c and IL-1b are likely to be the culprit. Such medi-
ators, which have been shown to induce endothelial expression of
both ICAM-1 (Pober, 1987) and VCAM-1 (Carlos et al., 1990), are
abundantly present in amyloid-burdened brains (Heneka et al.,
2015) and are highly expressed by AD-derived brain endothelial
cells (Grammas and Ovase, 2001).In addition to the VCAM-1 and ICAM-1 up-regulation, we have
also observed increased levels of MHC-I at perivascular sites in the
ArcAbmodel. Since only activated antigen-specific CD8+ T-cells are
able to cross the BBB (Galea et al., 2007), this finding would sup-
port the notion that antigen-presentation at perivascular sites
allows CD8+ T-cells infiltration into the brain parenchyma of ArcAb
mice. Taken together, our results suggest that amyloid-induced
endothelial cell activation might be responsible for T-cell infiltra-
tion in AD; further experiments are required to prove this
possibility.
Infiltrating T-cells are ideally positioned to directly interact and
potentially damage CNS-resident cells including neurons, astro-
cytes and microglia (Fig. 2D–F). Our results however do not sup-
port a cytotoxic role for T-cells in AD. Infiltrating T-cells in ArcAb
brains in fact did not actively proliferate nor displayed an effector
phenotype (Fig. 5); in agreement with our results, differentiated
CD8+ T-cells lacking cytolytic activity have been recently described
in white matter of AD and other neurological disorders (Smolders
et al., 2013). The phenotype observed in APP-tg mice is rather con-
sistent with an anergic or FoxP3 regulatory T-cell type. Regulatory
or anergic T-cells, while avoiding further neuronal damage, might
be limiting the beneficial activation of peripheral macrophages
and microglial cells. Lack of T-cell-derived IFN-c could impair
microglia and macrophages phagocytosis (Schroder et al., 2004).
Indeed, IFN-c overexpression was shown to increase phagocytosis
of Ab-plaques and promote macrophages infiltration in naïve
(Chakrabarty et al., 2010) as well as Ab-immunized APP-tg mice
(Monsonego et al., 2006); in the latter, however, clearance of Ab-
plaques came at the cost of T-cell-mediated encephalitis, suggest-
ing that a subtle temporal and regional regulation of IFN-c secre-
tion is crucial for proper immune reaction in AD. Furthermore,
regulatory or anergic T-cells might inhibit microglia phagocytic
activity via the focal release of anti-inflammatory cytokines such
as IL-10 and TGF-beta, both previously shown to modulate amyloid
build-up in transgenic models (Town et al., 2008; Guillot-Sestier
et al., 2015).
Supporting the possibility that the infiltrating T-cells play a reg-
ulatory role in amyloid-burdened brains, we have recently shown
that RAG2-deficient APP-PS1-dE9 mice lacking mature B and T-
cells display increased microglial phagocytic activity and lower
Ab burden (Spani et al., 2015). Furthermore, depletion of systemic
regulatory T-cells was found to modulate microglia and promote
amyloid clearance (Baruch et al., 2015). The exact mechanism of
T-cell mediated microglia responses remain to be elucidated.
At the moment it is not clear what causes the low T-cell prolif-
eration and activation state in amyloid-burdened brains. The pos-
sibility that Ab itself directly inhibits T-cells has been previously
proposed (Grant et al., 2012) and deserves further investigation.
In addition, our results imply impaired antigen presentation activ-
ity in the presence of amyloidosis. Indeed, we found only few
mature APCs in brain and CP samples of APP-tg mice (Fig. 6, Sup-
plementary Fig. 3 and Supplementary Table 1) and we provided
evidence for immature APCs in amyloid-burdened brains (Fig. 6,
Supplementary Figs. 2 and 4). These observations are in line with
previous reports indicating that exposure to Ab induces intracellu-
lar accumulation of MHC-II in human-derived DCs (Schmitt et al.,
1997) and lowers MHC-II production in murine primary microglia
(Butovsky et al., 2005); on the other hand, they are at odds with the
well-known up-regulation of MHC-II in AD samples (Rogers et al.,
1988; Parachikova et al., 2007) and tg models (Ferretti et al., 2011).
It is however possible that the up-regulation of MHC-II observed in
previous studies was driven by intracellular MHC-II accumulated
in immature APCs, which cannot be resolved via regular immuno-
histochemistry nor western blotting analysis. The lack of mature
APCs in the cerebrum and CP together with the increase in imma-
ture APCs cumulatively indicates scarce antigen-presentation
224 M.T. Ferretti et al. / Brain, Behavior, and Immunity 54 (2016) 211–225capability in APP-tg brains, which might contribute to low T-cell
activation. Immature APCs, in addition to their role in limiting anti-
gen presentation, might support a detrimental inflammatory state
in amyloid-burdened brains, since high intracellular levels of MHC-
II have been linked to TLR-triggered immune responses via Btk
activation (Liu et al., 2011).
5. Conclusions
Overall, our results suggest that amyloid deposition in brains is
accompanied by low T-cell activation and down-regulation of
antigen-presentation, supporting the concept of hypo-
responsiveness of the immune system to Ab (Monsonego et al.,
2001). It is likely that Ab phagocytosis is an immunological silent
phenomenon (Fitzner et al., 2011), which limits the activation of
the adaptive immune system to avoid detrimental autoimmunity.
However, in the long term, microglial and macrophage capability
to remove Ab might decline in the absence of T cell-derived stim-
ulatory factors and/or in response to T-cell derived inhibiting sig-
nalling. Elucidating the mechanism responsible for T-cell hypo-
responsiveness and its impact on microglia function could yield
novel therapeutic targets to AD.
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